Biotechnology · Boston, Massachusetts, United States
$2.98
-2.61% (-$0.08)2026-08-24
Smart-Money SignalNeutral · 53/100— Insider open-market flow is flat over 90 days
Net Income-$8.2M
EPS$-1.07
Market Cap$65.3M
Price Performance
Historical data including institutional events
Company Profile
R
Robert Connelly
CEO & Executive Director
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers.
Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
